Sign In
Buy REGN
$618.95
+16.03 (+2.66%)
At Close: Jun 03, 2026
Intellia (NTLA) Reports Positive Results for CRISPR Candidates
04:15pm, Monday, 19'th Sep 2022 Zacks Investment Research
Intellia Therapeutics (NTLA) reported positive interim results for its CRISPR candidates being evaluated to treat transthyretin (ATTR) amyloidosis and treating hereditary angioedema (HAE).
2 Biotech Stocks You Can Buy and Hold for the Next Decade
01:37pm, Monday, 19'th Sep 2022 The Motley Fool
It's hard to imagine a world in which pharmaceutical spending doesn't increase year in and year out.
Regeneron (REGN)/ Alnylam Report Promising Data from NASH Study
03:29pm, Friday, 16'th Sep 2022 Zacks Investment Research
Regeneron (REGN) and its partner Alnylam announce promising data from its ongoing phase I study evaluating ALN-HSD in healthy adults and NASH patients.
Regeneron (REGN)/ Alnylam Report Promising Data from NASH Study
12:48pm, Friday, 16'th Sep 2022
Regeneron (REGN) and its partner Alnylam announce promising data from its ongoing phase I study evaluating ALN-HSD in healthy adults and NASH patients.
Adverum (ADVM) Doses First Patient in the Mid-Stage wAMD Study
09:19pm, Thursday, 15'th Sep 2022 Zacks Investment Research
Adverum (ADVM) initiates dosing in the phase II LUNA study, currently investigating its lead product candidate ixoberogene soroparvovec for wet age-related macular degeneration.
Biotech Stock Roundup: BMY Surges on Drug Approval, REGN Up on Update & More
08:35pm, Wednesday, 14'th Sep 2022 Zacks Investment Research
Regulatory and pipeline updates from BMY and REGN are the key highlights from the biotech sector during the past week.
A Major October Catalyst Could Make This Eye Stock A Ten Bagger, Analyst Says
06:01pm, Tuesday, 13'th Sep 2022 Benzinga
Chardan initiated coverage on Outlook Therapeutics Inc (NASDAQ: OTLK) with a Buy rating and a price target of $10 based on the company's commercial potential with its lead ophthalmic formulation o
Is A Fall Imminent For Regeneron Stock After A Stellar 25% Rise In A Week?
08:00am, Tuesday, 13'th Sep 2022
Regeneron Pharmaceuticals stock (NASDAQ: REGN) is up a solid 25% in a week, while it has seen a 16% rise in a month, significantly outperforming the broader indices, with the S&P500 index rising 3.7%
Here's who could benefit from Biden's biotech initiative, according to Oppenheimer's Jared Holz
06:30pm, Monday, 12'th Sep 2022
Oppenheimer's Jared Holz on President Biden's cancer initiative and what it means for biotech in the U.S. With CNBC's Melissa Lee and the Fast Money traders, Tim Seymour, Courtney Garcia, Guy Adami an
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN ) Morgan Stanley 20th Annual Global Healthcare Conference September 12, 2022 11:05 AM ET Company Participants Ryan Crowe - VP of IR Leonard Schleifer - Fou
Regeneron Pharmaceuticals, Inc. (REGN) ESMO 2022 Investor Event (Transcript)
01:12pm, Monday, 12'th Sep 2022
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN ) ESMO 2022 Investor Event September 12, 2022 8:00 AM ET Company Participants Ryan Crowe - Head, IR David Weinreich - EVP, Global Clinical Development Isra
FAANG 2.0: Say Hello To MATANA, And Developments In Apple’s New Frontier
12:39pm, Saturday, 10'th Sep 2022 Investing.com
Wall Street Breakfast: What Moved Markets
12:30pm, Saturday, 10'th Sep 2022 Seeking Alpha
Listen on the go! A daily podcast of Wall Street Breakfast will be available this morning on Seeking Alpha, iTunes, Stitcher and Spotify. U.S.
Morgan Stanley just upgraded this large cap biotech stock
06:54pm, Friday, 09'th Sep 2022 Invezz
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) is now back to near its year-to-date high but a Morgan Stanley analyst says the stock is not done pleasing its investors yet. Regeneron stock has another 2
The 3 Best Healthcare Stocks to Buy Now
06:00pm, Friday, 09'th Sep 2022
With the exception of energy and utilities, all sectors of the S&P 500 are in the red for the year. Of the losing sectors, healthcare stocks have held up relatively well, outperformed only by consumer
